Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
Approval Alert | Three-Month Leuprolide Mesylate Formulation in Advanced Prostate Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Outlining Advances in AI For Breast Cancer Screening/Radiomics
5